Used in the treatment of type 1 diabetes, this antibody modulates the immune system by targeting CD3 receptors on T cells. It helps preserve pancreatic beta cell function, leading to improved insulin production and reduced dependency on exogenous insulin. The therapy is primarily investigated in newly diagnosed patients to slow disease progression. It has also been studied for immune tolerance induction, showing potential in reducing autoimmune attacks without broad immunosuppression.